ICG Distribution Using NIF Imaging After IV Injection of ICG in Benign and Malignant Breast Cancer Tissue.

Histological Study of the (Intravenously Injected) ICG Distribution in Tumor Bearing Breasts and in Axillary Pieces of Dissection.

The purpose of this study is to determine if NIF fluoresent imaging is an effctive approch to detect the margine of the breast tumoral tissue.

Primary objective:

Definition of the histological distribution (intravascular, extra vascular, in specific cells) of ICG (pre-operatively intra-venously injected) at the level of tumoral and healthy tissues of breast cancer patients (and the potential of axillary lymph nodes found fluorescent).

Secondary objectives:

Evaluation of the ability of the fluorescence imaging to determine the tumor volume and, more specifically, the boundaries of tumor tissues which will be analyzed by the pathologist.

Analysis of the correlation between fluorescence and "margins" as defined operatively as tumor (microscopically by the pathologist).

Inclusion Criteria:

• Patients with histopathological diagnosis of breast cancer for which a mastectomy with axillary dissection is planned.
• Informed Consent signed.

Exclusion Criteria:

• Diagnosis of breast cancer established by lumpectomy or "macro-biopsy".
• Operation after neo-adjuvant chemotherapy,
• Age less than 18 years.
• For pre-menopausal women, an operation planned for the second phase of their cycle.
• Inability to give informed consent.
• History of allergy or hypersensitivity to the investigational product, iodine.
• Clinical or biological hyperthyroidism.
• Known "toxic" thyroid nodules or known autonomous (hyperfunctional) thyroid.
• A reported pathological coronary artery disease.
• Creatinine > 1.5 mg / dl.
• During the 2 weeks before surgery, being on medications which are known to interfere with the ICG (ie anticonvulsants, heparin and haloperidol).
• Pregnancy or breast feeding period.